Peak Bio, Inc. develops innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Peak Bio, Inc.

Peak Bio Inc. | 789 followers on LinkedIn. Clinical-stage biopharmaceutical company. #PKBO | Our goal is to find innovative therapies that address significant unmet medical needs for patients with inflammatory, rare and specialty diseases, and cancer.

Notice to recruiters

All recruitment vendors (temporary staffing agencies, placement services, and professional recruiters) are prohibited from contacting our employees.

In order to be an authorized vendor partner for Peak Bio, all such organizations must have a formal written agreement with Peak Bio’s Human Resources Department. 

pH Pharma Inc. Director

신용남

Associate Director at pH Pharma Co., Ltd.

Mary Do

Drug discovery | ADCs | Bispecific antibodies | Immuno-oncology | Target validation | Cellular assays | In vivo models | Pharmacology

Mastewal Abuhay, PhD

teacher

Sheikh Mudasir

Peak Bio Inc.

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 15, 2024 6:37 AM	b0308403
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 15, 2024 6:37 AM	3fbd1838
crunchbase trigger	general	Nov 15, 2024 6:37 AM	2c8f25af
crunchbase profile	general	Nov 15, 2024 5:38 PM	afc48525
li profile	general	Nov 15, 2024 6:37 AM	571a9724
translate crunchbase fundingrounds	general
peers	general	Nov 15, 2024 6:37 AM	a6f52262
news basic	general	Nov 15, 2024 6:37 AM	4e95f0dd
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PEAK-BIO

Peak Bio, Inc.

Last Close

0.05

14/11 20:00

Market Cap

192.60K

Beta: -

Volume Today

1.93K

Avg: -